MedTrace Logo

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

NCT05135000 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2026-01-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to explore the efficacy and safety of LTP001 in participants with pulmonary arterial hypertension (PAH) to determine if LTP001 had an adequate clinical profile to warrant further clinical development in this indication.

Conditions

Interventions

DRUG

LTP001

LTP001, 6 mg, was administered orally once daily in the morning

DRUG

Placebo

Placebo to LTP001 was administered once daily in the morning

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2024-03-20
Completion
2024-04-25
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Germany
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05135000 on ClinicalTrials.gov